Loading...
XNAS
HEPA
Market cap626kUSD
Jun 06, Last price  
0.06USD
1D
34.35%
1Q
-33.14%
Jan 2017
-99.99%
IPO
-99.99%
Name

Contravir Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
3.76%
Rev. gr., 5y
%
Revenues
0k
Net income
-13m
L-73.04%
-842,970-5,280,842-14,347,877-16,998,638-14,891,050-15,022,184-9,449,295-7,037,338-20,353,938-32,722,168-42,200,049-48,926,042-13,192,420
CFO
-18m
L-55.45%
0-1,363,079-9,672,556-16,555,098-19,172,110-8,209,286-15,646,027-7,565,059-16,165,202-31,224,481-34,961,171-40,888,878-18,216,303
Earnings
Aug 11, 2025

Profile

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
IPO date
Feb 07, 2014
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑062016‑062015‑06
Income
Revenues
Cost of revenue
19,347
45,325
43,695
Unusual Expense (Income)
NOPBT
(19,347)
(45,325)
(43,695)
NOPBT Margin
Operating Taxes
2,969
409
(2,884)
Tax Rate
NOPAT
(22,316)
(45,734)
(40,811)
Net income
(13,192)
-73.04%
(48,926)
15.94%
(42,200)
28.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,495
(3,138)
BB yield
Debt
Debt current
2,900
232
54
Long-term debt
302
54
Deferred revenue
Other long-term liabilities
333
5,430
2,094
Net debt
2,494
(14,252)
(50,517)
Cash flow
Cash from operating activities
(18,216)
(40,889)
(34,961)
CAPEX
(14)
(16)
Cash from investing activities
(600)
(14)
(14)
Cash from financing activities
4,350
4,495
(5,138)
FCF
(23,037)
(45,844)
(40,487)
Balance
Cash
406
14,786
51,189
Long term investments
(565)
Excess cash
406
14,786
50,624
Stockholders' equity
(236,956)
(223,011)
(174,088)
Invested Capital
238,325
236,047
226,091
ROIC
ROCE
EV
Common stock shares outstanding
123
3,971
3,811
Price
Market cap
EV
EBITDA
(19,316)
(45,258)
(43,618)
EV/EBITDA
Interest
1,247
9
10
Interest/NOPBT